Acute heart failure (AHF) is classically defined by signs and symptoms related to elevated ventricular filling pressures. Regardless of precipitant, underlying etiology or ejection fraction, the vast majority of hospital admissions are the result of worsening chronic HF. For the acutely decompensated patient, 4 hemodynamic profiles, stratified by degree of congestion ("dry" or "wet") and adequacy of perfusion ("warm" or "cold") predict prognosis and guide therapy. Relief of congestion is the primary goal of AHF management. Loop diuretics remain the mainstay of AHF treatment, but new modalities such as veno-venous ultrafiltration are promising. For patients with evidence of hypoperfusion, vasoactive agents may be needed to facilitate diuresis. The decision to use vasodilators or inotropes is complex and the need for invasive hemodynamic monitoring is often determined by the individual patient's characteristics. Routine use of inotropes should be discouraged; however when used, the short-term hemodynamic benefits conferred by these agents must be balanced against their tendency to increase adverse events. Although these strategies are effective in alleviating symptoms in most patients, management dilemmas arise from cardiorenal interactions and limitations in effective novel therapies. Epidemiological studies continue to emphasize that AHF portends a poor prognosis. Further studies are needed to improve our understanding and outcomes in this growing patient population. (Circ J 2012; 76: 278 - 286) 
cute heart failure (AHF) is defined by the development of new-onset or worsening dyspnea as a consequence of high left ventricular filling pressures. Despite this simple definition, AHF represents a constellation of signs and symptoms that reflect heterogeneous etiologies and precipitants (Tables 1,2 ). 1, 2 The majority of hospital admissions (>75%) involve patients with chronic heart failure (HF), with either impaired or preserved systolic function, 3 and are associated with high rates of morbidity and mortality.
In the United States, nearly 5 million patients suffer from chronic HF with an incidence of 550,000 new cases diagnosed per year. 4 AHF accounts for more than 1 million annual hospitalizations and is the leading cause of hospital admission in patients older than 65 years. 4 Hospitalization for AHF is associated with a 30% readmission rate and 10% mortality within 60-90 days of hospital discharge. 2 These data emphasize both the epidemiologic and economic burden of this disease in the United States.
Over the past decade, several studies have characterized the epidemiology of HF within Japan. Adoption of Western lifestyles, an aging population, and improvement in therapies for coronary syndromes have led to a rise in the number of patients surviving with HF. 5 The Sado Heart Failure Study has projected an increase in the prevalence of HF from 979,000 patients in 2005 to 1.32 million patients by the year 2035. 6 Moreover, the Chronic Heart Failure Analysis and Registry in the Tohoku District (CHART)-2 study demonstrated that among symptomatic HF patients, 52 .5% of patients with Stage C HF and 74.7% of patients with Stage D HF had at least 1 hospitalization for AHF. 5 Thus, with a looming epidemic, a systematic approach to the management of AHF becomes paramount. The following review aims to provide an outline of the strategies for managing AHF.
Diagnosis
The diagnosis of AHF is made on the basis of a careful history, physical examination and investigations that confirm the presence of worsening volume overload.
Symptoms of AHF
Symptoms of AHF are dominated by those related to congestion, which is a reflection of elevated ventricular filling pressures. High left-sided filling pressures often result in orthopnea, paroxysmal nocturnal dyspnea, and dyspnea at rest or with minimal exertion. Elevated right-sided pressures, because of high left-sided pressures, pulmonary hypertension, or isolated right ventricular dysfunction, can manifest as right upper A 279 Hemodynamic Profiles for AHF Management quadrant discomfort, early satiety, anorexia, ascites, or edema. Of these symptoms, orthopnea has the greatest positive predictive value (66%) for elevated pulmonary capillary wedge pressure (PCWP; >22 mmHg). 7 Symptoms of low resting cardiac output (CO; <2.2 L · min -1 · m −2 ) are less specific and include lassitude, fatigue, decreased concentration, and daytime hypersomnolence. These symptoms may also result from sleep apnea and depression, both common comorbidities in patients with HF.
Physical Examination in AHF
The physical examination findings associated with elevated left-sided filling pressures include orthopnea, rales, a loud and leftward radiating P2, an audible S3, and an abnormal blood pressure response to the Valsalva maneuver. High right-sided pressures are reflected by the presence of jugular venous distention, hepatojugular reflux, hepatomegaly, ascites, and edema. However, in patients with decompensated chronic systolic HF, rales and edema are infrequently seen, because of increased lymphatic capacitance. In the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), rales were present in 20% and edema in 40% of AHF patients. 7 However, these findings are more prevalent in AHF secondary to HF with preserved ejection fraction (HFpEF). 8 Conversely, in some patients with chronic systolic HF, a change in the intensity of S3, rather than its presence, is a better indicator of AHF.
In AHF patients undergoing invasive hemodynamic monitoring, right and left-sided pressures are concordant in approximately 75% of patients such that right atrial pressure (RAP)= 1 /2 PCWP. 9 Accordingly, jugular venous pressure (JVP) is used to estimate RAP and is a reliable indicator of PCWP in most patients with AHF. 7 The square wave blood pressure response to the Valsalva maneuver, although infrequently performed, can also predict elevated PCWP with >90% sensitivity and specificity, 10 which is particularly useful in patients who have a difficult neck examination. Table 3 shows the correlation of different physical examination findings with invasively measured hemodynamic parameters in the ESCAPE trial. 7 Blood pressure is the most accessible measure of perfusion. Overt hypotension resulting in altered mentation and end-organ dysfunction is an obvious sign of compromised perfusion. A narrow proportional pulse pressure (pulse pressure/systolic blood pressure (SBP) <25%) and cold proximal extremities, are highly specific for a cardiac index <2.3 L · min -1 · m −2 , but are present infrequently in AHF. 7 In general, the accuracy of the physical examination for the assessment of a low CO is 
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limited (Table 3) . 7 However, physician assessment of a "cold" state determined by a constellation of physical examination and laboratory findings is predictive of a CO <2.3 L · min -1 · m −2 (Table 3 ). 7
Laboratory Markers in AHF
In addition to a careful history and physical examination, the US 11 and European 1 guidelines advocate that AHF patients receive an ECG, chest X-ray, and echocardiogram to assess potentially reversible etiologies and precipitants. Patients should also receive a diagnostic laboratory evaluation including a complete blood count, serum electrolytes, blood urea nitrogen (BUN), creatinine, glucose, albumin, hepatic enzymes, and international normalized ratio. These are important to assess Figure 1 . Bedside hemodynamic profiles in acute heart failure determined by the absence or presence of congestion (wet vs. dry) and adequacy of perfusion (warm vs. cold). Management should be directed towards achievement of a "warm and dry" profile with diuresis if "wet" and vasoactive therapy with diuresis if "wet and cold". Hemodynamic Profiles for AHF Management end-organ dysfunction and estimate prognosis. Hyponatremia, 12 and elevated BUN and creatinine 8,13 identify patients at risk for adverse outcomes and can be used to triage patients appropriately. Many AHF patients experience slight elevations in troponin; however, significant elevations may identify etiologies such as acute coronary syndrome or myocarditis. Furthermore, a positive troponin is associated with increased mortality in AHF. 14 B-type natriuretic peptides (BNP and NTproBNP) are useful for both diagnosis and prognosis in patients presenting to the emergency department with dyspnea of unclear etiology. 15, 16 Although elevated in most patients with AHF, a BNP level <100 ng/L 15 or NT-proBNP level <450 ng/L 16 may exclude AHF as the cause of dyspnea.
Assessment of Bedside Hemodynamic Profiles
Bedside evaluation of the AHF patient can provide important information about the degree of decompensation and overall prognosis. A simple strategy classifies patients into 4 specific hemodynamic profiles based on the absence or presence of congestion (wet or dry) and the adequacy of perfusion (warm or cold) ( Figure 1 ), where congestion is defined as a PCWP >18 mmHg and inadequate perfusion as a cardiac index <2.2 L · min -1 · m −2 . 17 In a series of 452 patients admitted to a tertiary hospital with AHF and systolic dysfunction, the majority were "wet and warm", followed by a "wet and cold" profile. 17 A "wet and cold" profile conferred an increased risk of death and cardiac transplantation at 1 year compared with a "wet and warm" profile, which in turn was associated with a 2-fold increased risk compared with a "dry and warm" profile. 17 
Treatment of AHF

Role of Pulmonary Artery Catheterization
These bedside hemodynamic profiles can be used successfully to guide therapy in AHF. However, in the patient whose clinical exam is unreliable, is refractory to empiric therapy, or has evidence of progressive end-organ dysfunction, invasive hemodynamic monitoring with a pulmonary artery catheter (PAC) may be considered to tailor therapy. Although previously a staple within critical care units, PAC use has become controversial out of concern for increased harm with little added clinical utility. The ESCAPE trial demonstrated that in hospitalized HF patients, use of the PAC did not increase inhospital mortality. 18 In experienced centers, PAC use enabled a trend for improved diuresis and functional capacity along with decreased left-sided pressures. However, 6-month rehospitalization and mortality were unaltered compared with therapy guided by bedside assessment alone. 18
Hemodynamic Goals of Therapy
Ideally, therapy based on these bedside clinical profiles should be targeted to achieve freedom from congestion or JVP <10 cmH2O. In patients with a PAC, therapy is usually targeted to achieve RAP <8 mmHg and PCWP <15 mmHg, respectively. 18 CO, per se, is not a goal of therapy. 19 However, therapy should be adjusted to maintain a blood pressure adequate for cerebral perfusion and not low enough to precipitate postural hypotension.
Using Bedside Hemodynamic Profiles to Guide Therapy
With these goals in mind, "wet and warm" patients may benefit solely from diuresis. Improvement in congestive symptoms can often be accelerated with additional use of intravenous vasodilators. Patients who are "wet and cold" will require vasoactive medications (inotropes or vasodilators) to augment perfusion in addition to diuretics (Figure 1 ). The "cold and dry" profile is rare and usually represents patients with significantly decreased contractile reserve without a tendency towards fluid retention. Alternatively, it might describe patients with severely dilated ventricles and dynamic mitral regurgitation who only develop symptoms with exertion. "Cold and dry" profile patients might require inotropic support but risk becoming inotrope-dependent. They might also benefit from biventricular pacing or surgical therapies aimed at improving myocardial efficiency. 17
Diuresis in the "Wet" Patient
Symptom relief is the primary objective of AHF management. Dyspnea because of pulmonary congestion is the consequence of high left ventricular filling pressures and worsening mitral regurgitation from increasing left ventricular volumes. In addition to improving exercise tolerance, 20 a reduction in filling pressures is associated with improved outcomes. 7, 21 Oxygen, morphine and non-invasive positive pressure ventilation 22 may alleviate respiratory distress in the acute setting. However, loop diuretics are the principle agents used to relieve congestion. In The Acute Decompensated Heart Failure National Registry (ADHERE), 88% of AHF patients received intravenous loop diuretics. 23 Despite concerns that high-dose diuretic therapy might lead to adverse outcomes, 24,25 the rapid symptomatic relief achieved with diuretics has led to their universal acceptance and has precluded randomized placebocontrolled trials for their use. Practice guidelines provide minimal guidance regarding loop diuretic dose and delivery. The Diuretic Optimization Strategies Evaluation trial (DOSE) randomized 308 AHF patients in a 2×2 factorial design to intravenous loop diuretics given either as a bolus every 12 h or as a continuous infusion, at a dose that was either equivalent to the patient's previous oral dose or 2.5-fold that dose. 26 There were no differences in patients' global assessments of symptoms, change in renal function, or in the composite secondary endpoint of death or re-hospitalization or emergency department visits at 60 days irrespective of diuretic dose or delivery strategy. However, high-dose furosemide resulted in greater net fluid loss, weight loss, relief from dyspnea, and fewer serious adverse events than low-dose furosemide, albeit at the cost of increased worsening renal function (WRF). These data suggest a benefit with high-dose diuretic therapy, but the study was underpowered to draw any firm conclusions regarding optimal diuretic administration.
Veno-venous ultrafiltration is an additional modality that can be used successfully to relieve congestion. The Ultrafiltration versus Intravenous Diuretics for Patients Hospitalized with Acute Decompensated HF trial (UNLOAD) randomized 200 patients with AHF to receive ultrafiltration or intravenous diuretics within 24 h of hospitalization. 27 Ultrafiltration resulted in greater fluid and weight loss at 48 h relative to diuretics (P<0.001). Ultrafiltration also significantly reduced 90-day HF re-hospitalization compared to diuretics (P=0.037). Despite its efficacy, use of ultrafiltration is limited by the need for largebore venous access, systemic anticoagulation, and the shorthalf-life and expense associated with ultrafiltration filters. For these reasons, ultrafiltration is typically reserved to facilitate faster fluid removal in patients with large reservoirs of volume or for those refractory to standard diuretic treatment. Moreover, in patients with significant volume overload, the rate of ultrafiltration should be adjusted to safely mobilize fluid from the extravascular to the intravascular space to avoid precipitat-
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Vasodilation to Relieve Congestion (Table 4)
Although trial data is limited, intravenous vasodilators used in addition to diuretics, may improve congestive symptoms, particularly in patients with hypertensive AHF. In ADHERE, 10% of patients received intravenous nesiritide (recombinant human brain-type natriuretic peptide) and an additional 11% were treated with nitroglycerin or nitroprusside. 23 In the Vasodilation in the Management of AHF trial (VMAC), intravenous nesiritide lowered PCWP at 3 and 24 h compared with both placebo and nitroglycerin. It also improved dyspnea at 3 h relative to placebo, but not nitroglycerin. 28 However, upon further evaluation in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated HF trial (ASCEND-HF) involving 7,141 AHF patients, nesiritide failed to significantly improve dyspnea, and importantly, 30 day re-hospitalization and mortality relative to placebo. 29 Thus, the role of nesiritide in AHF management remains undefined. The effect of nitroglycerin and nitroprusside on outcomes in AHF has not been evaluated. Regardless, when intravenous vasodilators are used, patients should be transitioned to oral vasodilator agents including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and occasionally nitrates and hydralazine, once freedom from congestion is achieved. Vasodilator use is associated with an increased incidence of symptomatic hypotension. 28,29 Therefore, vasodilators are not recommended in patients with SBP <90 mmHg or severe obstructive valvular disease. 1, 11 In general, nitroglycerin and nesiritide, but not nitroprusside, can be used without invasive blood pressure monitoring. Additionally, nitroprusside infusion can be complicated by cyanide toxicity, which increases with dose, duration, and hepatic dysfunction. Cyanide levels should therefore be monitored in patients receiving nitroprusside.
Cardiorenal Syndrome Complicating Diuresis
A large proportion of AHF patients have concomitant renal dysfunction. 2, 8 The presence of renal insufficiency is associated with adverse outcomes 8, 13 and promotes diuretic resistance, defined as a reduced natriuretic response to a given dose of loop diuretics. This often requires administration of higher doses of loop diuretics or a combination of loop and non-loop diuretics, such as thiazides, for adequate diuresis. However, in 20-25% of patients, aggressive diuresis is accompanied by WRF, defined as an increase in serum creatinine >26.52 micromol/L or a >25% decline in estimated glomerular filtration rate relative to baseline. 13 The development of WRF is associated with longer lengths of stay, higher readmission rates, and increased mortality. 30, 31 The pathogenesis underlying WRF in AHF is complex and is thought to be related to neurohormonal activation and alterations in peripheral and renal vascular resistance leading to renal injury (Figure 2) . 32 In the absence of overt hypotension, these mechanisms are thought to be largely independent of CO 13 and instead are correlated with increased RAP and intra-abdominal pressures. 33, 34 Indeed, in small studies, a reduction in RAP and intra-abdominal pressures can improve renal function in patients with AHF. 33, 34 Damman et al have proposed a schema for the treatment of renal dysfunction in AHF that parallels the bedside hemodynamic profiles, but instead is based on elevations in RAP and adequacy of renal blood flow (Figure 3) . 32 Several novel strategies have been evaluated to prevent WRF during AHF treatment. Initial studies suggested that nesiritide would attenuate deleterious neurohormonal activation, promote renal vasodila- tion, and thus increase natriuresis and diuresis while preserving renal function. 35 Another strategy involved the specific vasopressin-2 receptor antagonist, tolvaptan. Vasopressin levels are elevated in chronic HF and promote water reabsorption in the collecting duct of the kidney. It was postulated that tolvaptan, added to standard therapy, would augment aquaresis, correct hyponatremia, and prevent renal deterioration. 36 Lastly, activation of the adenosine-1 receptor in the kidney stimulates sodium and water reabsorption in the proximal tubule. Furthermore, adenosine stimulates tubuloglomerular feedback to promote afferent arteriolar vasoconstriction and a reduction in GFR. In early studies adenosine receptor antagonists, when given in conjunction with diuretics, increased diuresis while preserving renal function. 37 Unfortunately, in large randomized trials of AHF, none of these agents has shown a significant benefit in terms of diuresis or prevention of WRF compared with standard diuretic therapy. 29,38,39 Ultrafiltration, while effective at promoting diuresis, also did not confer any renal protection relative to loop diuretics. 27 Interestingly, a recent analysis from ESCAPE demonstrated that achieving adequate diuresis, measured by evidence of hemoconcentration, improved outcomes in AHF despite the development of WRF. 40 Once again, this study highlights the complex relationship between the heart and the kidney. Treatment of patients with the cardiorenal syndrome remains challenging with the hope that ongoing studies will advance our understanding of cardiorenal interactions and help direct therapy.
Treatment of the "Cold" Patient
AHF patients presenting with a "wet and cold" profile may require vasoactive support (Table 4 ). In the extreme, cardiogenic shock is defined as significant hypotension (SBP <90 mmHg) because of impaired contractility (cardiac index <2.2 ml · min -1 · m −2 ) leading to high intra-cardiac filling pressures (PCWP >15 mmHg) and marked tissue hypoperfusion.
In patients with cardiogenic shock, intravenous inotropes should be administered acutely to improve cardiac contractility and systemic perfusion until the underlying cause of shock is determined and treated. In these instances, dopamine is often the inotrope of choice. At doses of 5-20 μg · kg -1 · min -1 , dopamine increases cardiac contractility and heart rate via activation of β-adrenergic receptors and mediates vasoconstriction through activation of α-receptors in the periphery. If blood pressure cannot be maintained with increasing doses of dopamine, epinephrine can be used as a more potent α and β adrenergic agonist. Norepinephrine may occasionally be considered when abnormal vasodilation is suspected. Because of the increased risk of tachyarrhythmias, myocardial ischemia, and renal and peripheral ischemic injury, epinephrine and norepinephrine are usually reserved for life-threatening circumstances. 41 Patients unresponsive to medical therapy may require additional mechanical circulatory support. 42 Discussion of mechanical support devices in AHF is beyond the scope of this review.
"Wet and cold" patients with marginal blood pressures, may benefit from short-term inotropic therapy to improve symptoms and end-organ perfusion. In these circumstances, the most commonly used inotropes include the β-adrenergic agonists dopamine and dobutamine, and the phosphodiesterase inhibitor, milrinone. 41 These agents increase the intracellular concentration of calcium via increased cAMP, thereby augmenting the force of actin-myosin interaction, the velocity of muscle fiber shortening and ultimately, cardiac contractility. 43 In addition, both dobutamine and milrinone increase CO through peripheral vasodilation and a reduction in cardiac afterload. Milrinone is a more potent inodilator that reduces right and left ventricular filling pressures, as well as mean arterial pressure to a greater extent than dobutamine. 44 Therefore, the choice between dobutamine and milrinone is often influenced by the balance between a greater increase in heart rate and myocardial oxygen consumption with dobutamine and a greater risk of hypotension with milrinone. 44 It is further influenced by the higher cost of milrinone and its longer halflife, which is further prolonged by renal dysfunction. 41 There is also the suggestion that patients on chronic β-adrenergic blockade respond better to milrinone than dobutamine if they require inotropes. 45 However, the short-term hemodynamic benefits conferred by these agents may be compromised by their potential to induce arrhythmias, exacerbate ischemia, and increase myocardial oxygen demand.
Despite their widespread use, there are limited data evaluating outcomes with inotropic agents in AHF. In the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbation of Chronic Heart Failure study (OPTIME-CHF), 951 hospitalized patients were randomized to a 48 h infusion of milrinone or placebo. 46 The use of milrinone was associated with a higher rate of early treatment failure, sustained hypotension, and atrial arrhythmias. There was also a non-significant trend towards increased in-hospital and 60-day mortality with milrinone. 46 However, the mean SBP in this trial was 120 mmHg, making it likely that these patients were "warm" and not "cold". The results of this trial suggest that the routine use of inotropes in "wet and warm" patients is not often necessary and may in fact be detrimental.
Levosimendan is a novel calcium-sensitizing agent that increases myocardial contractility without increasing myocardial oxygen consumption and opens potassium ATP channels to promote vasodilation and end-organ perfusion. Based on its mechanism of action and the positive results of early clinical trials, 47 it was postulated that levosimendan, unlike β-adrenergic agonists, would improve hemodynamics without precipitating ischemia or arrhythmias. Unfortunately, in the Survival of Patients with AHF in Need of Intravenous Inotropic Support study (SURVIVE) comparison of levosimendan to dobutamine in 1,327 AHF patients, did not show a benefit in symptom relief, mortality, or arrhythmias with levosimendan. 48 Currently, levosimendan is not approved for clinical use in the US. However, it is available in Europe as an add-on therapy for AHF refractory to standard treatment.
In a subset of "cold and wet" patients, intrinsic neurohormonal activation results in peripheral vasoconstriction that limits CO, thereby preventing adequate unloading of the ventricle. In these instances, hemodynamics may be improved by either intravenous vasodilators or inotropes. The decision to use vasodilators vs. inotropes may be guided either by a preserved SBP or a high systemic vascular resistance determined invasively. Though not restricted to "wet and cold" patients, retrospective analyses of ESCAPE 49 and the ADHERE Registry 23 have shown increased rates of HF re-hospitalization and mortality with inotropes, but not with vasodilators, compared with no vasoactive therapy. However, in the absence of invasive hemodynamic monitoring, the advantages of intravenous vasodilation need to be balanced against the risk of hypotension. On the other hand, routine addition of intravenous inotropic therapy to all patients with acute decompensated HF is not warranted and could increase morbidity and mortality. In general, the decision between inotrope and vasodilator, depends on the individual patient's hemodynamic profile. When warranted, the lowest effective inotropic dose should be used, and Hemodynamic Profiles for AHF Management duration of treatment minimized as much as possible with an early transition to appropriate oral therapy.
Inotrope-Dependent AHF
The hallmark features of true inotrope-dependence include an inability to wean vasoactive therapy without precipitating hypotension (SBP <80 mmHg), end-organ dysfunction, and signs and symptoms of worsening HF. 50 In such patients, inotropic therapy may be maintained for longer periods either as a bridge to transplantation, bridge to ventricular assist device placement, or as palliative therapy to improve symptoms at the end of life.
Optimization at Discharge
Although majority of patients experience an improvement in their presenting signs and symptoms after treatment, the rates of mortality and readmission after an index hospitalization remain high. 2 Up to 45% of patients have incomplete resolution of symptoms at the time of discharge. 8 Results from ES-CAPE demonstrate that patients who continue to have a "wet" or "cold" profile after AHF treatment have a significantly increased risk of adverse outcomes at 6 months compared with those who are "warm and dry" at discharge (hazard ratio 1.5, P=0.017). 7 Therefore, patients should be diuresed aggressively until they are free of clinical congestion at rest and are not symptom-limited with ambulation on the ward. A dry weight should be established and patients should be monitored on an oral diuretic regimen for at least 24 h to establish the dose necessary to maintain optimal fluid balance after discharge. Underlying precipitants, such as ischemia, arrhythmia, and non-cardiac comorbidities, such as pneumonia, should be adequately addressed to prevent readmission. 2 There are significant gaps between guideline recommendations and utilization of HF therapies. 51 Evidence-based therapies should be instituted prior to discharge to improve longterm outcomes. Patients should receive education regarding healthy lifestyles, dietary discretion, medication adherence, and monitoring for and response to changes in fluid status. This can be facilitated by early follow-up within 1-2 weeks after discharge to ensure adherence and clinical stability. 52 Lastly, HF disease management programs have consistently been shown to reduce HF hospitalizations 53 and should be used to the extent possible, especially for high-risk patients.
AHF in Patients With HF With Preserved EF
More than half the patients in ADHERE and OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with HF) had HFpEF. 8, 54 Despite this, there are no clinical trials or guidelines that specifically target AHF in HFpEF patients. The treatment of these patients is based on the data described above for patients with systolic dysfunction. However, both ADHERE and OPTIMIZE-HF highlight that HFpEF patients differ significantly from those with systolic HF. They tend to be older, female, and with a higher incidence of comorbidities including hypertension, diabetes, atrial fibrillation, and chronic lung disease. Interestingly, fewer patients with HFpEF have a history of ischemic heart disease. The presenting signs and symptoms of patients with HFpEF and those with systolic HF are similar except that HFpEF patients tend to have higher SBP. Accordingly, fewer HFpEF patients receive vasoactive therapies and are treated primarily with intravenous diuretics. The degree of symptomatic improvement at the time of discharge is similar in both groups, although the in-patient mortality is lower in the HFpEF group. Despite this, 90-day mortality and re-hospitalization rates are similar, perhaps because of the lack of evidencebased therapies for the management of chronic HFpEF. Trials targeted at both the acute and chronic management of patients with HFpEF are urgently needed to better serve this large subset of HF patients.
Conclusions
AHF management is underscored by both pharmacologic and mechanical solutions that improve symptoms, relieve volume overload and enhance perfusion. Early clinical recognition and delivery of optimal therapy will help reduce the morbidity and mortality associated with this ever-growing epidemic.
